Skip to main content

Newsroom

Press Releases

November 20, 2017
GAITHERSBURG, Md., Nov. 20, 2017 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for the manufacture of ACAM2000®, (Smallpox (Vaccinia) Vaccine, Live) in th...

 


Corporate Headquarters Ribbon Cutting

Media
Lynn R. Kieffer
kiefferl@ebsi.com 
TEL 240-631-3391 

Investors
Robert Burrows 
burrowsr@ebsi.com 
TEL 240-631-3280